Aveanna Healthcare Holdings Inc. — Form 8-K Summary
Business Context and Reporting Period
Filed July 15, 2021, with the report signed July 20, 2021. The filing reports an amendment to Aveanna Healthcare LLC’s existing first-lien credit agreement. It does not provide quarterly or annual operating results.
Material Financing Changes
- All outstanding first-lien term loans were converted into a single $860.0 million 2021 Extended Term Loan.
- A $200.0 million delayed-draw term loan facility was established, available through July 15, 2023, subject to specified conditions. It was undrawn as of July 15, 2021.
- The maturity date for the converted term loans was extended from March 2024 to July 2028. Any delayed-draw borrowings also mature in July 2028.
- The amendment simplifies the loan structure and reduces overall interest rates, while modifying default thresholds and certain covenants concerning asset sales, prepayments, indebtedness, liens, investments and affiliate transactions.
Interest Rates, Liquidity and Other Terms
- Borrowers may elect a variable rate based on LIBOR, subject to a 0.50% floor, or the Annual Base Rate, subject to a 2.00% floor.
- Applicable margins are 3.75% for LIBOR-based loans and 2.75% for Annual Base Rate loans, subject to adjustments under the amended agreement.
- The $860.0 million extended term loan was accruing interest at 4.25% as of the filing.
- The delayed-draw facility provides potential additional debt capacity but had no outstanding balance at closing. The filing does not provide a current cash balance, leverage ratio, cash flow, operating margin or other liquidity metrics.
- Voluntary prepayments are generally permitted without premium or penalty, subject to minimum amounts. A 1.00% premium may apply during the first six months to certain repricing transactions.
Outlook, Risks and Unusual Items
The amendment increases maturity flexibility and permits additional secured borrowings, but also leaves the company with substantial secured debt. Future delayed-draw borrowings are subject to conditions in the credit agreement and could increase interest expense and leverage. The filing provides no management earnings guidance or broader business outlook.
Key Facts for Investors to Verify
- Terms, covenants, events of default and conditions governing the $200.0 million delayed-draw facility.
- The company’s total debt, leverage, interest expense and compliance with applicable covenants after the amendment.
- Whether and when delayed-draw term loans are incurred before July 15, 2023.
- The effect of the revised interest-rate provisions and any subsequent changes in benchmark rates.
- The complete Extension Amendment filed as Exhibit 10.1, including omitted schedules available from the company or the SEC upon request.